Lower-concentration NSAID reduces pain, inflammation after cataract surgery

Bromfenac ophthalmic solution 0.07% dosed once daily reduced intraocular inflammation and pain after cataract surgery when compared with placebo, according to a study. In two prospective, double-masked, phase 3 clinical trials, 222 patients randomized to receive once-daily Prolensa (bromfenac ophthalmic solution 0.07%, Bausch + Lomb) experienced less pain and inflammation and fewer adverse events than did 218 patients randomized to receive placebo. The dosing regimen was followed for 16 days: one drop the day before cataract surgery with posterior chamber IOL implantation, one drop the day of surgery and one (Read more...)

Full Story →